[Opioid anesthetics (sufentanil and remifentanil) in neuro-anaesthesia].
Remifentanil is the latest available compound of the 4-anilidopiperidine derivatives. It is characterized by an ultrashort duration of action and a metabolism independent of both hepatic and renal functions. Its main drawback is a lack of residual analgesia and the risk of postoperative hyperalgesia. Since its introduction in clinical practice, this drug has been compared to other congeners in a few studies in the setting of neurosurgery. Cerebral hemodynamics, intracranial pressure and CO(2) reactivity are similar to the effects of fentanyl and sufentanil provided that systemic arterial pressure is maintained. Haemodynamics does not greatly vary according to the type of the opioid. Fentanyl and sufentanil require higher hypnotic dosage (halogenated agents, propofol) and remifentanil is accompanied by greater volumes of fluid infusion. A marked reduction in extubation times and superior level of consciousness are reported with remifentanil. Rescue analgesic has to be given faster but pain scores remain low. Morphine 0.08 mg/kg IV administered at bone replacement results in good postoperative analgesia without delayed recovery. In summary, remifentanil is appropriate when rapid recovery and neurological evaluation are desired. Conversely, sufentanil is more suitable and easier to administer when postoperative mechanical ventilation and postponed awakening are scheduled.
Viviand
X
X
Département d'anesthésie-réanimation et centre de traumatologie, hôpital Nord, 13915 Marseille cedex 20, France. xviviand@ap-hm.fr
Garnier
F
F
D000701:Analgesics, Opioid; D018686:Anesthetics, Intravenous; D000818:Animals; D006801:Humans; D019635:Neurosurgical Procedures; D010880:Piperidines; D000077208:Remifentanil; D017409:Sufentanil
D000701:Analgesics, Opioid; D018686:Anesthetics, Intravenous; D010880:Piperidines; D017409:Sufentanil; D000077208:Remifentanil